Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials

BACKGROUND: Breast cancer is the most common cancer in women in the U.S. and Western Europe. Amplification of the her-2/neu gene occurs in approximately 25% of invasive ductal carcinomas of the breast. The first HER-2/neu-targeted approach to reach the clinic was trastuzumab, a humanized monoclonal...

Descripción completa

Detalles Bibliográficos
Autores principales: Viani, Gustavo A, Afonso, Sergio L, Stefano, Eduardo J, De Fendi, Ligia I, Soares, Francisco V
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1959236/
https://www.ncbi.nlm.nih.gov/pubmed/17686164
http://dx.doi.org/10.1186/1471-2407-7-153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1959236/
https://www.ncbi.nlm.nih.gov/pubmed/17686164
http://dx.doi.org/10.1186/1471-2407-7-153

Ejemplares similares